MUSE vs. Mesenchymal Stem Cells: Differences & Which is Better?
Written by Dr. David Greene, MD, PhD, MBA on March 11, 2026
If you’ve been researching regenerative medicine, you may have come across a newer term making waves in the stem cell world — MUSE stem cells. At R3 Stem Cell, we’ve been receiving a growing number of questions about MUSE cells, how they differ from traditional mesenchymal stem cells (MSCs), and whether they represent a significant upgrade in treatment.
Dr. David Green, founder and CEO of R3 Stem Cell, breaks down the key differences so you can make an informed decision about your care.
MUSE stands for Multilineage-differentiating Stress-Enduring cells. Despite the buzz, MUSE cells are not an entirely new type of stem cell. They are a naturally occurring subpopulation within the mesenchymal stem cell population — making up roughly 3% of the total MSC count in any given sample, including umbilical cord tissue-derived MSCs.
This means that if you’ve ever received umbilical cord mesenchymal stem cell therapy, you’ve already received MUSE cells as part of that treatment. The difference is that MUSE cells can now be isolated and concentrated using specialized equipment that identifies specific cell surface markers, allowing them to be separated from the broader MSC population.
There are several notable distinctions between MUSE cells and standard mesenchymal stem cells.
The “SE” in MUSE stands for stress-enduring. MUSE cells demonstrate a superior ability to survive in low-oxygen (hypoxic) environments compared to regular MSCs. This characteristic offers theoretical advantages, particularly when cells are introduced into damaged or inflamed tissue where oxygen levels may be compromised. While the full clinical significance of this trait is still being studied, it is a promising area of research.
One of the most exciting aspects of MUSE cells is their position on the potency spectrum. Standard mesenchymal stem cells are classified as multipotent, meaning they can differentiate into a limited range of cell types such as bone, cartilage, and fat cells. MUSE cells, however, are considered closer to being pluripotent — a state in which a cell can theoretically differentiate into virtually any cell type in the body.
This shift from multipotent toward pluripotent capability represents a meaningful advancement in regenerative potential, especially considering that MUSE cells have not been associated with increased risk of tumor formation or immune rejection — concerns that sometimes arise with other pluripotent cell types like embryonic stem cells or iPSCs.
Mesenchymal stem cells are backed by an extensive body of evidence, with over 1,000 peer-reviewed published studies documenting their safety and therapeutic benefits across a wide range of conditions. MUSE cells, being a more recently isolated subpopulation, currently have approximately a dozen peer-reviewed clinical research studies supporting their use.
The existing MUSE cell research indicates a strong safety profile and has shown encouraging clinical trends in patients with conditions such as stroke, ALS (amyotrophic lateral sclerosis), and other central nervous system disorders. As research continues to expand, the evidence base for MUSE cells is expected to grow significantly.
At R3 Stem Cell, MUSE cell therapy is administered via intravenous (IV) infusion, which is consistent with how all published clinical trials on MUSE cells have been conducted to date. Treatment protocols typically involve either 20 million or 40 million MUSE cells per session.
Because MUSE cells are considered more potent than standard MSCs on a per-cell basis, dosing is adjusted accordingly — patients generally receive a lower total cell count compared to a traditional MSC infusion while still achieving robust therapeutic exposure.
R3 Stem Cell offers MUSE stem cell therapy at all three clinic locations in Mexico:
Both umbilical cord mesenchymal stem cell therapy and the concentrated MUSE cell subpopulation are available, allowing patients and their care team to select the most appropriate treatment protocol based on individual needs and clinical goals.
| Feature | Mesenchymal Stem Cells (MSCs) | MUSE Stem Cells |
| Cell Type | Full MSC population | Subpopulation of MSCs (~3%) |
| Potency | Multipotent | Closer to pluripotent |
| Stress Tolerance | Standard | Enhanced (stress-enduring) |
| Tumor Risk | Very low | Very low |
| Published Studies | 1,000+ peer-reviewed | ~12 peer-reviewed clinical studies |
| Administration | IV, intrathecal, direct injection | IV infusion |
| Typical Dose | Higher cell counts | 20–40 million cells |
Whether you’re exploring stem cell therapy for a neurological condition, autoimmune disorder, orthopedic injury, or general wellness optimization, understanding the difference between standard MSCs and MUSE cells can help guide your treatment decisions.
To find out if you’re a candidate for MUSE stem cell therapy or umbilical cord mesenchymal stem cell treatment, contact R3 Stem Cell today at +1-844-GET-STEM or visit R3 Stem Cell to learn more.
This content is based on insights from Dr. David Green, founder and CEO of R3 Stem Cell, the global leader in regenerative therapies with over 28,000 procedures performed worldwide. R3 Stem Cell operates clinics in Tijuana, Cancun, and Puerto Vallarta, Mexico.
Disclaimer: Stem cell therapy is an evolving field of medicine. Results may vary by individual. This content is for informational purposes and does not constitute medical advice. Consult with a qualified healthcare provider to determine if stem cell therapy is appropriate for your condition.
Contact Us